Moreover , treatment with selective serotonin reuptake inhibitor compared to placebo was associated with a significant reduction in estimated mean depressive symptoms measured by SCL-90 ( P = .03 ) and BDI ( P = .048 ) , but not with MADRS ( P = .64 ) .